Amgen Inc at JPMorgan Healthcare Conference Transcript
Good morning, everybody. I'm Chris Schott at JPMorgan, and it's my pleasure to be introducing Amgen today. From the company, we have Bob Bradway, the company's Chairman and CEO. Obviously, a very productive 2023 for the company and really looking forward to Bob's comments as we think about the story going forward. So with that, I'll turn it over to Bob.
Okay. Good morning. Thank you, Chris, for your introduction, and thank you all for being here this morning. I would say heading into 2024 at Amgen, we're feeling very enthusiastic about the prospects of our being able to deliver attractive long-term growth for our shareholders and real value for the patients and staff at the company. So we're excited about the long-term outlook for our business, but also excited about what's in prospect in 2024.
Okay. You're familiar with the safe harbor statement. I'll move off that briskly. Let me just quickly remind you
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |